삼성서울병원

Ko En

Park, Joon Oh M.D , M.D., Ph.D

TITLE
Professor Division of Hematology/Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine
Treament Schedule 01 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
MON
31
AM
PM
Treament Schedule 02 月
DATE
TUE
01
WEB
02
THU
03
FRI
04
SAT
05
SUN
06
MON
07
TUE
08
WEB
09
THU
10
FRI
11
SAT
12
SUN
13
MON
14
TUE
15
WEB
16
THU
17
FRI
18
SAT
19
SUN
20
MON
21
TUE
22
WEB
23
THU
24
FRI
25
SAT
26
SUN
27
MON
28
AM
PM

Medical School

Yonsei University Medical College

Specialty Training

Fellowship   Yonsei Cancer Center
Samsung Medical Center Division of Hematology/Oncology
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Residency   Yonsei Medical Center, Severance Hospital
Internship   Yonsei Medical Center, Severance Hospital

Clinical & Research Interests

Pancreatic cancer
Bliary tract cancer
Colon cancer
Clinical and translational research with molecularly targeted agents

Participation in Academic Societies
and Research

Member of European Society of Medical Oncology
Member of American Association of Cancer Research
Member of American Society of Clinical Oncology
Member of Korean Cancer Study Group
Member of Korean Cancer Association
Member of Korean Association of Internal Medicine

Selected Publications

  • J HEPATO-BIL-PAN SCI 2021 10.1002/jhbp.986 Multi-biomarker panel prediction model for diagnosis of pancreatic cancer Lee1, DH; Yoon, W; Lee, A; Han, Y; Byun, Y; Kang, JS; Kim, H; Kwon, W; Suh, YA; Choi, Y; Namkung, J; Han, S; Yi, SG; Heo, JS; Han, IW; Park, JO; Park, JK; Kim, SC; Jun, E; Kang, CM; Lee, WJ; Lee, HK; Lee, H; Lee, S; Jeong, SY; Lee, KE; Han, W; Park, T; Jang, JY
    View PubMed
  • ESMO OPEN 2021 10.1016/j.esmoop.2021.100049 Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) Park1, HS; Kang, B; Chon, HJ; Im, HS; Lee, CK; Kim, I; Kang, MJ; Hwang, JE; Bae, WK; Cheon, J; Park, JO; Hong, JY; Kang, JH; Kim, JH; Lim, SH; Kim, JW; Kim, JW; Yoo, C; Choi, HJ
    View PubMed
  • J CLIN ONCOL 2021 10.1200/JCO.20.02232 Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) Hecht1, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY
    View PubMed
  • CANCERS 2021 10.3390/cancers13071647 Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review Yoo1, C; Shin, SH; Park, JO; Kim, KP; Jeong, JH; Ryoo, BY; Lee, W; Song, KB; Hwang, DW; Park, JH; Lee, JH
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed